KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $222.3 million.

  • Adaptive Biotechnologies' Cash & Current Investments fell 12.56% to $212.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $826.4 million, marking a year-over-year decrease of 30.59%. This contributed to the annual value of $222.3 million for FY2024, which is 35.83% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Cash & Current Investments stood at $222.3 million for FY2024, which was down 35.83% from $346.4 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Cash & Current Investments high stood at $688.3 million for FY2020, and its period low was $222.3 million during FY2024.
  • For the 3-year period, Adaptive Biotechnologies' Cash & Current Investments averaged around $355.6 million, with its median value being $346.4 million (2023).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Cash & Current Investments slumped by 48.70% in 2021, and later skyrocketed by 41.11% in 2022.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Cash & Current Investments stood at $688.3 million in 2020, then tumbled by 48.70% to $353.1 million in 2021, then spiked by 41.11% to $498.2 million in 2022, then crashed by 30.47% to $346.4 million in 2023, then plummeted by 35.83% to $222.3 million in 2024.